Baseline activity of telavancin against gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 702-706

  Mendes, Rodrigo E ^a   Farrell, David J ^a   Sader, Helio S ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN DERIVATIVE; TEICOPLANIN; TELAVANCIN; TETRACYCLINE; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; ANTIBIOTIC RESISTANCE; CROSS INFECTION; DRUG EFFECTS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; UNITED STATES;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; UNITED STATES;

EID: 84920165557     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04052-14     Document Type: Article

References (25)

1. Theravance, Inc. 2014. Vibativ package insert. Theravance, Inc., San Francisco, CA.
2. Rubinstein E, Stryjewski ME, Barriere SL. 2014. Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on nonventilator- associated pneumonia. Infect Drug Resist 7:129-135. http://dx.doi.org/10.2147/IDR.S25930.
3. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME. 2011. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis 52:31-40. http://dx.doi.org/10.1093/cid/ciq031.
4. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 46:1683-1693. http://dx.doi.org/10.1086/587896.
5. Kosowska-Shick K, Clark C, Pankuch GA, McGhee P, Dewasse B, Beachel L, Appelbaum PC. 2009. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob Agents Chemother 53:4217-4224. http://dx.doi.org/10.1128/AAC.00742-09.
6. Krause KM, Blais J, Lewis SR, Lunde CS, Barriere SL, Friedland HD, Kitt MM, Benton BM. 2012. In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 74:429-431. http://dx.doi.org/10.1016/j.diagmicrobio.2012.08.010.
7. Steed ME, Vidaillac C, Rybak MJ. 2012. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 56:955-959. http://dx.doi.org/10.1128/AAC.05849-11.
8. Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV. 2011. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents 37:558-561. http://dx.doi.org/10.1016/j.ijantimicag.2011.02.007.
9. Twilla JD, Gelfand MS, Cleveland KO, Usery JB. 2011. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. J Antimicrob Chemother 66:2675-2677. http://dx.doi.org/10.1093/jac/dkr329.
10. Marcos LA, Camins BC. 2010. Successful treatment of vancomycinintermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrob Agents Chemother 54:5376-5378. http://dx.doi.org/10.1128/AAC.00857-10.
11. Saravolatz LD, Pawlak J, Johnson LB. 2012. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycinresistant Staphylococcus aureus isolates. Clin Infect Dis 55:582-586. http://dx.doi.org/10.1093/cid/cis492.
12. Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE, Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49:1127-1134. http://dx.doi.org/10.1128/AAC.49.3.1127-1134.2005.
13. Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR, Jr, Moeck G. 2008. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother 52:1597-1603. http://dx.doi.org/10.1128/AAC.01513-07.
14. Rennie RP, Koeth L, Jones RN, Fritsche TR, Knapp CC, Killian SB, Goldstein BP. 2007. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. J Clin Microbiol 45:3151-3154. http://dx.doi.org/10.1128/JCM.02411-06.
15. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Farrell DJ, Mendes RE, Rhomberg PR, Jones RN. 2014. Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies. Antimicrob Agents Chemother 58:5547-5551. http://dx.doi.org/10.1128/AAC.03172-14.
17. Ross JE, Mendes RE, Jones RN. 2014. Quality control MIC ranges for telavancin when applying a revised CLSI reference broth microdilution method. J Clin Microbiol 52:3399-3401. http://dx.doi.org/10.1128/JCM.01210-14.
18. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-9th ed. CLSI M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
19. EUCAST. 2014. Breakpoint tables for interpretation of MICs and zone diameters, version 4.0. http://www.eucast.org/clinical-breakpoints/.
20. Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG. 2011. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 69:342-347. http://dx.doi.org/10.1016/j.diagmicrobio.2010.10.031.
21. Mendes RE, Sader HS, Farrell DJ, Jones RN. 2012. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007-2009). Diagn Microbiol Infect Dis 72:113-117. http://dx.doi.org/10.1016/j.diagmicrobio.2011.09.023.
22. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. 2008. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 52:2383-2388. http://dx.doi.org/10.1128/AAC.01641-07.
23. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. 2008. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 62:116-121. http://dx.doi.org/10.1093/jac/dkn124.
24. Mendes RE, Sader HS, Flamm RK, Jones RN. 2014. Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. J Antimicrob Chemother 69:1579-1581. http://dx.doi.org/10.1093/jac/dku016.
25. Jones RN, Flamm RK, Sader HS. 2013. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis 76:122-123. http://dx.doi.org/10.1016/j.diagmicrobio.2013.01.003.